Outcomes of the Treatment with Glecaprevir/Pibrentasvir following heart transplantation utilizing hepatitis C viremic donors.

Alex Reyentovich Claudia G GideaDeane SmithBonnie E LonzeZachary KonAnthony FargnoliJennifer PavoneShaline RaoTajinderpal SaraonTyler LewisYingzhi QianIra JacobsonNader Moazami

Published in: Clinical transplantation (2020)

Our center reports excellent outcomes in transplanting utilizing hearts from HCV-VIR donors. No effect on survival or co-morbidity was found. An 8-week GLE/PIB course was safe and effective when initiated approximately 1 week post-transplant.

Keyphrases

hepatitis c virus
kidney transplantation
randomized controlled trial
computed tomography
glycemic control
hiv infected
study protocol
smoking cessation
antiretroviral therapy